Loading...
XNAS
CMND
Market cap722kUSD
Dec 04, Last price  
0.13USD
1D
18.99%
1Q
-87.17%
IPO
-99.93%
Name

Clearmind Medicine Inc

Chart & Performance

D1W1MN
XNAS:CMND chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
221.94%
Rev. gr., 5y
%
Revenues
0k
Net income
-5m
L-56.05%
-6,671-194,535-105,283-233,220-4,122,652-9,410,806-11,955,031-5,254,678
CFO
-5m
-9,124-105,588-63,006-264,452-2,835,029-5,083,5610-4,858,659

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
IPO date
May 15, 2018
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT